ArticleFrontiers in immunology2017
Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.Experimental hematology & oncology · 2024Review
- Review
- P2X7 receptor activation impairs antitumour activity of natural killer cells.British journal of pharmacology · 2023Article
- Current progress in NK cell biology and NK cell-based cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2020Review
- A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.Journal of immunology research · 2020Article
- Article
- Editorial: Modulation of Human Immune Parameters by Anticancer Therapies.Frontiers in immunology · 2020Article
- Mechanisms of resistance to CAR T cell therapy.Nature reviews. Clinical oncology · 2019Review
- Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2019Article
- Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector FunctionsFrontiers in immunology · 2019Article
- The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction.Cancers · 2018Review
- Challenges of NK cell-based immunotherapy in the new era.Frontiers of medicine · 2018Review
- NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.Frontiers in immunology · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies based on natural killer (NK) cells are among the most promising therapies under development for the treatment of so far incurable forms of leukemia and other types of cancer. The importance of NK cells for the control of viral infections and cancer is supported among others by the findings that viruses and tumors use a multitude of mechanisms to subvert and evade the NK cell system. Infections and malignant diseases can further lead to the shaping of NK cell populations with altered reactivity. Counter measures of potential therapeutic impact include the blocking of inhibitory interactions between NK cell receptors and their cellular ligands, the enhancement of activating receptor signals, and the infusion of large numbers of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.